Vertex Pharmaceuticals Incorporated (VRTX)

$450.97

+0.6

(+0.13%)▲

Market is closed - opens 8 PM, 25 Nov 2024
star icon

Vertex Pharmaceuticals Incorporated is a biotechnology company that develops and commercializes treatments for cystic fibrosis and other serious medical conditions.

Performance

  • $449.18
    $455.37
    $450.97
    downward going graph

    0.4%

    Downside

    Day's Volatility :1.36%

    Upside

    0.97%

    downward going graph
  • $346.29
    $519.88
    $450.97
    downward going graph

    23.21%

    Downside

    52 Weeks Volatility :33.39%

    Upside

    13.25%

    downward going graph

Returns

PeriodVertex Pharmaceuticals IncorporatedSector (Health Care)Index (NASDAQ Composite)
3 Months
-6.29%
-7.3%
6.3%
6 Months
0.04%
-0.5%
13.5%
1 Year
27.74%
10.5%
33.2%
3 Years
141.35%
8.8%
20.5%

Highlights

Market Capitalization
116.0B
Book Value
$60.65
Earnings Per Share (EPS)
-1.89
PEG Ratio
1.18
Wall Street Target Price
514.18
Profit Margin
-4.51%
Operating Margin TTM
40.82%
Return On Assets TTM
12.05%
Return On Equity TTM
-2.98%
Revenue TTM
10.6B
Revenue Per Share TTM
41.19
Quarterly Revenue Growth YOY
11.600000000000001%
Gross Profit TTM
5.3B
EBITDA
4.4B
Diluted Eps TTM
-1.89
Quarterly Earnings Growth YOY
0.01
EPS Estimate Current Year
0.53
EPS Estimate Next Year
18.92
EPS Estimate Current Quarter
4.14
EPS Estimate Next Quarter
4.08

Analyst Recommendation

Buy
    68%Buy
    26%Hold
    5%Sell
Based on 38 Wall street analysts offering stock ratings for Vertex Pharmaceuticals Incorporated(by analysts ranked 0 to 5 stars)
Based on 38 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
26
26
26
Hold
10
10
8
Sell
2
2
2

Analyst Forecast

What analysts predicted

Upside of 14.02%

Current $450.97
Target $514.18

Company Financials

FY18Y/Y Change
Revenue
3.0B
↑ 22.46%
Net Income
2.1B
↑ 695.83%
Net Profit Margin
68.8%
↑ 58.21%
FY19Y/Y Change
Revenue
4.2B
↑ 36.59%
Net Income
1.2B
↓ 43.88%
Net Profit Margin
28.27%
↓ 40.53%
FY20Y/Y Change
Revenue
6.2B
↑ 49.07%
Net Income
2.7B
↑ 130.43%
Net Profit Margin
43.7%
↑ 15.43%
FY21Y/Y Change
Revenue
7.6B
↑ 22.06%
Net Income
2.3B
↓ 13.63%
Net Profit Margin
30.92%
↓ 12.78%
FY22Y/Y Change
Revenue
8.9B
↑ 17.91%
Net Income
3.3B
↑ 41.84%
Net Profit Margin
37.2%
↑ 6.28%
FY23Y/Y Change
Revenue
9.9B
↑ 10.51%
Net Income
3.6B
↑ 8.96%
Net Profit Margin
36.68%
↓ 0.52%
Q2 FY23Q/Q Change
Revenue
2.5B
↑ 4.99%
Net Income
915.7M
↑ 30.85%
Net Profit Margin
36.73%
↑ 7.26%
Q3 FY23Q/Q Change
Revenue
2.5B
↓ 0.39%
Net Income
1.0B
↑ 13.06%
Net Profit Margin
41.69%
↑ 4.96%
Q4 FY23Q/Q Change
Revenue
2.5B
↑ 1.38%
Net Income
968.8M
↓ 6.42%
Net Profit Margin
38.48%
↓ 3.21%
Q1 FY24Q/Q Change
Revenue
2.7B
↑ 6.73%
Net Income
1.1B
↑ 13.5%
Net Profit Margin
40.92%
↑ 2.44%
Q2 FY24Q/Q Change
Revenue
2.6B
↓ 1.95%
Net Income
-3.6B
↓ 426.81%
Net Profit Margin
-136.4%
↓ 177.32%
Q3 FY24Q/Q Change
Revenue
2.8B
↑ 5.21%
Net Income
1.0B
↓ 129.09%
Net Profit Margin
37.71%
↑ 174.11%
FY18Y/Y Change
Total Assets
6.2B
↑ 76.14%
Total Liabilities
1.8B
↑ 20.42%
FY19Y/Y Change
Total Assets
8.3B
↑ 33.18%
Total Liabilities
2.2B
↑ 23.34%
FY20Y/Y Change
Total Assets
11.8B
↑ 41.27%
Total Liabilities
3.1B
↑ 37.25%
FY21Y/Y Change
Total Assets
13.4B
↑ 14.3%
Total Liabilities
3.3B
↑ 8.73%
FY22Y/Y Change
Total Assets
18.2B
↑ 35.13%
Total Liabilities
4.2B
↑ 27.18%
FY23Y/Y Change
Total Assets
22.7B
↑ 25.23%
Total Liabilities
5.1B
↑ 21.51%
Q2 FY23Q/Q Change
Total Assets
20.3B
↑ 7.25%
Total Liabilities
4.9B
↑ 7.42%
Q3 FY23Q/Q Change
Total Assets
21.7B
↑ 6.77%
Total Liabilities
5.2B
↑ 6.85%
Q4 FY23Q/Q Change
Total Assets
22.7B
↑ 4.62%
Total Liabilities
5.1B
↓ 1.22%
Q1 FY24Q/Q Change
Total Assets
23.9B
↑ 5.22%
Total Liabilities
5.4B
↑ 4.29%
Q2 FY24Q/Q Change
Total Assets
20.1B
↓ 15.83%
Total Liabilities
5.4B
↓ 0.25%
Q3 FY24Q/Q Change
Total Assets
22.2B
↑ 10.47%
Total Liabilities
6.6B
↑ 23.37%
FY18Y/Y Change
Operating Cash Flow
1.3B
↑ 50.34%
Investing Cash Flow
-202.2M
↓ 53.81%
Financing Cash Flow
-71.2M
↓ 204.12%
FY19Y/Y Change
Operating Cash Flow
1.6B
↑ 23.54%
Investing Cash Flow
-1.2B
↑ 511.07%
Financing Cash Flow
126.8M
↓ 278.0%
FY20Y/Y Change
Operating Cash Flow
3.3B
↑ 107.32%
Investing Cash Flow
99.4M
↓ 108.05%
Financing Cash Flow
-505.3M
↓ 498.57%
FY21Y/Y Change
Operating Cash Flow
2.6B
↓ 18.75%
Investing Cash Flow
-340.9M
↓ 443.0%
Financing Cash Flow
-1.5B
↑ 192.51%
FY22Y/Y Change
Operating Cash Flow
4.1B
↑ 56.23%
Investing Cash Flow
-321.1M
↓ 5.81%
Financing Cash Flow
-67.7M
↓ 95.42%
Q2 FY23Q/Q Change
Operating Cash Flow
1.1B
↑ 26.06%
Investing Cash Flow
-303.9M
↓ 83.43%
Financing Cash Flow
17.3M
↓ 105.87%

Technicals Summary

Sell

Neutral

Buy

Vertex Pharmaceuticals Incorporated is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.06%
0.04%
27.74%
141.35%
101.98%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-21.61%
-24.74%
-7.55%
13.66%
101.19%
Biontech Se
Biontech Se
1.94%
14.27%
14.47%
-63.37%
445.2%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-16.95%
63.94%
50.31%
30.85%
117.83%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.18
0.53
-0.03
0.12
NA
60.65
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.41
18.41
1.11
44.91
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.04
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$116.0B
101.98%
32.84
-4.51%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$81.8B
101.19%
18.41
33.61%
Biontech Se
Biontech Se
Buy
$25.9B
445.2%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$31.8B
117.83%
NA
-15.86%

Insights on Vertex Pharmaceuticals Incorporated

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 2.63B → 2.77B (in $), with an average increase of 5.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -3.59B → 1.04B (in $), with an average increase of 443.8% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 50.3% return, outperforming this stock by 22.6%

Institutional Holdings

  • Capital World Investors

    10.41%

  • Vanguard Group Inc

    8.99%

  • BlackRock Inc

    8.28%

  • State Street Corp

    4.55%

  • FMR Inc

    4.09%

  • Capital Research Global Investors

    3.50%

Company Information

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.

Organization
Vertex Pharmaceuticals Incorporated
Employees
5400
CEO
Dr. Jeffrey Marc Leiden M.D., Ph.D.
Industry
Health Technology

FAQs